ETC
CRSP icon

Exchange Traded Concepts’s CRISPR Therapeutics CRSP Stock Holding History

Exchange Traded Concepts’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
+19,578
New +$1.03M ﹤0.01% 909
2025
Q3 		– Sell
-18,555
Closed -$903K – 1465
2025
Q2 		$903K Buy
+18,555
New +$718K 0.01% 719
2025
Q1 		– Sell
-16,127
Closed -$635K – 1292
2024
Q4 		$635K Sell
16,127
-3,065
-16% -$145K 0.01% 747
2024
Q3 		$902K Buy
19,192
+3,563
+23% +$181K 0.02% 556
2024
Q2 		$844K Buy
15,629
+3,650
+30% +$211K 0.02% 496
2024
Q1 		$816K Buy
+11,979
New +$858K 0.02% 488
2023
Q2 		– Sell
-22,185
Closed -$1M – 1325
2023
Q1 		$1M Buy
+22,185
New +$1.08M 0.03% 329
2021
Q2 		– Sell
-342
Closed -$42K – 1130
2021
Q1 		$42K Buy
342
+39
+13% +$5.89K ﹤0.01% 825
2020
Q4 		$46K Sell
303
-5,285
-95% -$625K ﹤0.01% 746
2020
Q3 		$467K Buy
5,588
+1,477
+36% +$131K 0.03% 317
2020
Q2 		$302K Buy
4,111
+1,963
+91% +$115K 0.05% 372
2020
Q1 		$91K Buy
2,148
+1,254
+140% +$64.7K 0.05% 266
2019
Q4 		$54K Buy
+894
New +$48.8K 0.01% 274

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Exchange Traded Concepts's CRSP Position: Q2 2026 in Review

Exchange Traded Concepts opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 19,578 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #909 among its holdings. This is a return to the name: Exchange Traded Concepts previously reported a position in CRSP as recently as Q2 2025.

Exchange Traded Concepts first reported a position in CRSP in Q4 2019 and has held it in 13 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Exchange Traded Concepts held 19,578 shares of CRISPR Therapeutics worth $1.07M as of Q2 2026.
  • CRISPR Therapeutics was a new Exchange Traded Concepts position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #909 holding.
  • Exchange Traded Concepts first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.